The phrase "all prognoses" is correct and usable in written English.
It can be used when referring to multiple predictions or forecasts, typically in a medical or analytical context.
Example: "After reviewing all prognoses, the team decided to adjust their strategy accordingly."
Alternatives: "all predictions" or "all forecasts".
For seven sweltering rounds, against all prognoses, Ali allowed Foreman, the brutish, one-blow Goliath, actually to punch himself out on his arms, as Ali himself lay on the ropes, head back as if out of a bedroom window to check if the cat was on the roof.
A remarkable part of Hazel's story is that she has been in hospice for longer than most patients, defying all prognoses on life expectancy.
cIAP2, along with BAX and BMF has been proposed as a three-gene signature for acute myeloid leukemia (ALL) prognosis but there have been contrasting reports for the importance of elevated levels of IAPs in other forms of leukemias.
NOTCH1 mutations alone or in combination with FBXW7 did not impact T-ALL prognosis.
In addition to the poor over-all prognosis the course of the disease is often complicated by thromboembolic events.
In our series the status of NOTCH1 mutations alone or in combination with FBXW7 did not impacted in T-ALL prognosis.
Since the first report addressing the role of NOTCH1 mutations in paediatric T-ALL prognosis, several controversial issues have been raised regarding the actual impact of these mutations on prognosis [ 7].
Given this evidence, we hypothesized that analysis of NOTCH1 in concert with genes functionally related to Notch1 pathway, such as FBXW7, KRAS and PTEN, would provide additional relevant information regarding T-ALL prognosis.
Aberrantly expressed FLT3 has been observed at high levels in a spectrum of hematologic malignancies, including 70% to 100% of AML, B-ALL, a fraction of T-Cell ALL, and CML in lymphoid blast crisis [ 31]; however, this is the first report that evaluated its potential role and association to B-ALL prognosis.
Despite improved rates of remission and cure in newly diagnosed adult acute lymphoblastic leukemia (ALL), the prognosis for patients with relapsed or refractory disease remains poor and the 5-year overall survival rate after relapse is under 10%.
This involved 211 (81.2%) of all the prognosis papers.
